Characterizing clinical and biologic features of persistent hypoxemic respiratory failure

持续性低氧性呼吸衰竭的临床和生物学特征

基本信息

  • 批准号:
    10690151
  • 负责人:
  • 金额:
    $ 0.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-05-16 至 2023-05-15
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY/ABSTRACT Research: Acute hypoxemic respiratory failure (AHRF) requiring mechanical ventilation is a common, costly condition with high mortality, yet treatment remains supportive. Identifying effective targeted therapeutics in heterogeneous conditions like AHRF depends on characterizing subsets, or sub-phenotypes, of patients with high likelihood of disease related events or response to therapy. This project will characterize a novel sub- phenotype called persistent hypoxemic respiratory failure (PHRF) among mechanically ventilated AHRF patients, with PHRF defined by ongoing mechanical ventilation and hypoxemia on ICU day 3. Using clinical trajectory to define sub-phenotypes in other heterogeneous syndromes has helped delineate patients with distinct prognosis and highlight biologic mechanisms contributing to trajectories. With large, independent prospective ICU cohorts from the University of Washington and Vanderbilt University, Dr. Sathe will address the following aims: (1) identify clinical factors on ICU day 1 associated with PHRF (2) determine biologic features of PHRF by analyzing ICU day 1 and day 3 circulating biomarkers of lung injury and (3) develop and validate a multivariable model that predicts PHRF on ICU day 3. Understanding risk factors for PHRF will help hone in on the early mechanisms important for pathologic responses to lung injury. Advantages to sub- phenotyping within AHRF rather than ARDS (where prior efforts were focused) include expanding the scope of patients we target for therapy and improving reliability of study definitions. In addition, discriminating between patients who will and will not develop PHRF will aid clinical prognostication, resource allocation, and targeted trial enrollment of patients unlikely to improve with existing treatment. The results will fill key knowledge gaps prioritized by the NHLBI regarding which factors determine risk for persistent hypoxemia, and the degree to which these factors overlap across ARDS and other conditions in AHRF. Candidate/Environment: With the support of the University of Washington, Dr. Mark Wurfel, Dr. Catherine “Terri” Hough, and biostatistician Leila Zelnick, PhD, this award will help establish Dr. Sathe’s career as a translational physician-scientist practicing Pulmonary and Critical Care. Through the proposed research, she will develop fundamental skills for analysis of longitudinal cohort data, contemporary machine learning methods for prediction, and high-quality measurement and analysis of lung injury biomarkers. This work will identify biologic pathways for more in-depth study in prospective AHRF cohorts, which she will pursue in a future K23. She plans to establish a career examining the heterogeneity of acute respiratory failure and other ICU syndromes, to advance the development of targeted therapeutics for critically ill patients.
项目总结/摘要 研究:需要机械通气的急性低氧性呼吸衰竭(AHRF)是一种常见的,昂贵的 死亡率高,但治疗仍然支持。确定有效的靶向治疗方法, 像AHRF这样的异质性疾病取决于患者的特征子集或亚表型, 疾病相关事件或治疗反应的可能性较高。该项目将描绘一个新的子- 机械通气AHRF中的持续性低氧性呼吸衰竭(PHRF)表型 患者,PHRF定义为ICU第3天持续机械通气和低氧血症。使用临床 在其他异质性综合征中定义亚表型的轨迹有助于描述 不同的预后和突出的生物学机制有助于轨迹。大型、独立 来自华盛顿大学和范德比尔特大学的预期ICU队列,Sathe博士将在 以下目的:(1)确定ICU第1天与PHRF相关的临床因素(2)确定生物学 通过分析ICU第1天和第3天肺损伤的循环生物标志物来评估PHRF的特征,以及(3)发展和 验证预测ICU第3天PHRF的多变量模型。了解PHRF的风险因素将有助于 研究肺损伤病理反应的早期重要机制。优势分- 在AHRF而不是ARDS(先前的努力集中)中进行表型分析包括扩大 我们治疗的目标患者,并提高研究定义的可靠性。此外,区分 将要和不会发展PHRF的患者将有助于临床诊断、资源分配和有针对性的治疗。 试验入组的患者不太可能通过现有治疗改善。结果将填补关键的知识空白 NHLBI优先考虑哪些因素决定了持续性低氧血症的风险,以及 这些因素在ARDS和AHRF的其他条件下重叠。 候选人/环境:在华盛顿大学的支持下,Mark Wurfel博士、Catherine博士 “Terri”Hough和生物统计学家Leila Zelnick博士,这个奖项将有助于建立Sathe博士的职业生涯, 从事肺部和重症监护的转化医学科学家。通过这项研究,她 将发展分析纵向队列数据的基本技能,当代机器学习 用于预测的方法,以及肺损伤生物标志物的高质量测量和分析。这项工作将 确定生物学途径,以便在前瞻性AHRF队列中进行更深入的研究,她将在 未来的K23她计划建立一个职业生涯,研究急性呼吸衰竭和其他疾病的异质性。 ICU综合征,以促进危重患者靶向治疗的发展。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Alveolar Biomarker Profiles in Subphenotypes of the Acute Respiratory Distress Syndrome.
急性呼吸窘迫综合征亚表型的肺泡生物标志物概况。
  • DOI:
    10.1097/ccm.0000000000005704
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    8.8
  • 作者:
    Sathe,NehaA;Morrell,EricD;Bhatraju,PavanK;Fessler,MichaelB;Stapleton,ReneeD;Wurfel,MarkM;Mikacenic,Carmen
  • 通讯作者:
    Mikacenic,Carmen
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Neha Alhad Sathe其他文献

Neha Alhad Sathe的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Neha Alhad Sathe', 18)}}的其他基金

Characterizing clinical and biologic features of persistent hypoxemic respiratory failure
持续性低氧性呼吸衰竭的临床和生物学特征
  • 批准号:
    10231616
  • 财政年份:
    2021
  • 资助金额:
    $ 0.25万
  • 项目类别:
Characterizing clinical and biologic features of persistent hypoxemic respiratory failure
持续性低氧性呼吸衰竭的临床和生物学特征
  • 批准号:
    10462490
  • 财政年份:
    2021
  • 资助金额:
    $ 0.25万
  • 项目类别:

相似海外基金

Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 0.25万
  • 项目类别:
    Research Grant
The Association Between Aging, Inflammation, and Clinical Outcomes in Acute Respiratory Distress Syndrome
衰老、炎症与急性呼吸窘迫综合征临床结果之间的关联
  • 批准号:
    10722669
  • 财政年份:
    2023
  • 资助金额:
    $ 0.25万
  • 项目类别:
Sedatives Pharmacology in Acute Respiratory Distress Syndrome- SPA
急性呼吸窘迫综合征中的镇静药理学 - SPA
  • 批准号:
    491387
  • 财政年份:
    2023
  • 资助金额:
    $ 0.25万
  • 项目类别:
    Fellowship Programs
New mechanism-based TREM-1 therapy for acute respiratory distress syndrome
基于新机制的 TREM-1 疗法治疗急性呼吸窘迫综合征
  • 批准号:
    10678788
  • 财政年份:
    2023
  • 资助金额:
    $ 0.25万
  • 项目类别:
Great Lakes Clinical Center of the Acute Respiratory Distress Syndrome, Pneumonia and Sepsis (APS) Consortium
急性呼吸窘迫综合征、肺炎和败血症 (APS) 联盟五大湖临床中心
  • 批准号:
    10646578
  • 财政年份:
    2023
  • 资助金额:
    $ 0.25万
  • 项目类别:
Effect of ADAMTS13 on pathogenesis of acute respiratory distress syndrome
ADAMTS13 对急性呼吸窘迫综合征发病机制的影响
  • 批准号:
    23K08447
  • 财政年份:
    2023
  • 资助金额:
    $ 0.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)
一种新型合成生物学衍生的微生物疗法,可治疗病毒引起的急性呼吸窘迫综合征(ARDS)
  • 批准号:
    10601865
  • 财政年份:
    2023
  • 资助金额:
    $ 0.25万
  • 项目类别:
Development of drug therapy targeting ferroptosis, iron-dependent cell death for acute respiratory distress syndrome.
开发针对铁死亡(急性呼吸窘迫综合征的铁依赖性细胞死亡)的药物疗法。
  • 批准号:
    23K08360
  • 财政年份:
    2023
  • 资助金额:
    $ 0.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Sustainable Implementation of Prone Positioning for the Acute Respiratory Distress Syndrome
持续实施俯卧位治疗急性呼吸窘迫综合征
  • 批准号:
    10722194
  • 财政年份:
    2023
  • 资助金额:
    $ 0.25万
  • 项目类别:
Point-of-care system to assess the risk of trauma-induced acute respiratory distress syndrome
用于评估创伤引起的急性呼吸窘迫综合征风险的护理点系统
  • 批准号:
    10594793
  • 财政年份:
    2023
  • 资助金额:
    $ 0.25万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了